BRPI1013227A2 - pró-fármacos transportadores de interferon alfa - Google Patents
pró-fármacos transportadores de interferon alfaInfo
- Publication number
- BRPI1013227A2 BRPI1013227A2 BRPI1013227A BRPI1013227A BRPI1013227A2 BR PI1013227 A2 BRPI1013227 A2 BR PI1013227A2 BR PI1013227 A BRPI1013227 A BR PI1013227A BR PI1013227 A BRPI1013227 A BR PI1013227A BR PI1013227 A2 BRPI1013227 A2 BR PI1013227A2
- Authority
- BR
- Brazil
- Prior art keywords
- transporter
- prodrugs
- interferon alpha
- interferon
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09154449 | 2009-03-05 | ||
| EP09180477 | 2009-12-22 | ||
| PCT/EP2010/052745 WO2010100220A1 (en) | 2009-03-05 | 2010-03-04 | Interferon alpha carrier prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013227A2 true BRPI1013227A2 (pt) | 2016-03-29 |
Family
ID=42041523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013227A BRPI1013227A2 (pt) | 2009-03-05 | 2010-03-04 | pró-fármacos transportadores de interferon alfa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120058084A1 (pt) |
| EP (1) | EP2403537A1 (pt) |
| JP (1) | JP2012519666A (pt) |
| CN (1) | CN102413843A (pt) |
| AU (1) | AU2010220324A1 (pt) |
| BR (1) | BRPI1013227A2 (pt) |
| CA (1) | CA2753001A1 (pt) |
| MX (1) | MX2011008963A (pt) |
| RU (1) | RU2011140219A (pt) |
| WO (1) | WO2010100220A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| DK2459171T3 (en) | 2009-07-31 | 2017-09-25 | Sanofi Aventis Deutschland | Long-acting insulin composition |
| KR20120089843A (ko) | 2009-07-31 | 2012-08-14 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린 링커 접합체를 포함한 프로드럭 |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| AU2010311421B2 (en) | 2009-10-29 | 2014-11-20 | Ascendis Pharma A/S | Sterilization of biodegradable hydrogels |
| EP2512450B1 (en) | 2009-12-15 | 2018-02-07 | Ascendis Pharma Endocrinology Division A/S | Dry growth hormone composition transiently linked to a polymer carrier |
| EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| ES2500048T3 (es) | 2010-09-14 | 2014-09-29 | F. Hoffmann-La Roche Ag | Procedimiento para purificar eritropoyetina pegilada |
| EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
| FR2975301B1 (fr) | 2011-05-20 | 2013-05-24 | Flamel Tech Sa | Composition comprenant un interferon alpha |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8383093B1 (en) * | 2011-11-01 | 2013-02-26 | Serina Therapeutics, Inc. | Subcutaneous delivery of poly(oxazoline) conjugates |
| MY186106A (en) | 2012-10-11 | 2021-06-22 | Ascendis Pharma As | Diagnosis, prevention and treatment of diseases of the joint |
| KR102608645B1 (ko) | 2014-11-18 | 2023-12-01 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | 신규한 중합체성 hGH 프로드러그 |
| EP4732848A3 (en) | 2014-11-21 | 2026-07-29 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| JP7524206B2 (ja) | 2019-03-04 | 2024-07-29 | アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス | 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3812507A1 (de) | 1988-04-15 | 1989-10-26 | Sachsenwerk Ag | Schaltfeld fuer eine gekapselte mittelspannungs-schaltanlage |
| DE19510438A1 (de) | 1995-03-22 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von 1,4-Butandiol und Tetrahydrofuran aus Furan |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US20050271615A1 (en) | 2002-08-30 | 2005-12-08 | Doron Shabat | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
| EP1625855A1 (en) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Polymeric prodrug with a self-immolative linker |
| CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
-
2010
- 2010-03-04 CN CN2010800192302A patent/CN102413843A/zh active Pending
- 2010-03-04 US US13/254,869 patent/US20120058084A1/en not_active Abandoned
- 2010-03-04 BR BRPI1013227A patent/BRPI1013227A2/pt not_active Application Discontinuation
- 2010-03-04 MX MX2011008963A patent/MX2011008963A/es not_active Application Discontinuation
- 2010-03-04 RU RU2011140219/15A patent/RU2011140219A/ru not_active Application Discontinuation
- 2010-03-04 JP JP2011552445A patent/JP2012519666A/ja active Pending
- 2010-03-04 AU AU2010220324A patent/AU2010220324A1/en not_active Abandoned
- 2010-03-04 WO PCT/EP2010/052745 patent/WO2010100220A1/en not_active Ceased
- 2010-03-04 CA CA2753001A patent/CA2753001A1/en not_active Abandoned
- 2010-03-04 EP EP10706648A patent/EP2403537A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN102413843A (zh) | 2012-04-11 |
| EP2403537A1 (en) | 2012-01-11 |
| JP2012519666A (ja) | 2012-08-30 |
| US20120058084A1 (en) | 2012-03-08 |
| RU2011140219A (ru) | 2013-04-10 |
| WO2010100220A1 (en) | 2010-09-10 |
| AU2010220324A1 (en) | 2011-09-01 |
| MX2011008963A (es) | 2012-02-01 |
| CA2753001A1 (en) | 2010-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301211I1 (nl) | Olipudase alfa | |
| NL301210I1 (nl) | Avalglucosidase alfa | |
| NO2020033I1 (no) | andeksanet alfa | |
| SMT201600351B (it) | Composti antivirali | |
| FI20095967L (fi) | Valaisinsovitelma | |
| EP3832204C0 (en) | USER-WEARABLE LIGHTING ASSEMBLY | |
| PL2414015T4 (pl) | System laryngoskopowy | |
| HUE032917T2 (hu) | 1-es típusú interferon diagnosztikum | |
| EP4220743C0 (en) | LIGHT EMITTING DIODE | |
| PT2483389T (pt) | Estirpes de shigella com hipervesiculação | |
| BR112012001777A2 (pt) | serigrafia | |
| BRPI1010661A2 (pt) | peptídeo | |
| NL300948I2 (nl) | velmanase alfa | |
| BRPI0922716A2 (pt) | purificação de polipeptídeo | |
| FR2947857B1 (fr) | Agencement de deshuileur | |
| BR112012001722A2 (pt) | projetor de led | |
| DK3696491T3 (da) | Leddelt målestok | |
| FI20096192L (fi) | Kohteen valaiseminen | |
| DE102009055010A8 (de) | Dachanordnung | |
| FI20096108A0 (fi) | Järjestely | |
| EP2683644A4 (en) | Transport apparatus | |
| FI20090342L (fi) | Henkilökuljetin | |
| NO20093038A (no) | Skip | |
| CR10574S (es) | Bloques alfa | |
| DOS2009000074S (es) | Molduras |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/60 (2017.01) |